F I R S T  A N N O U N C E M E N T

10th INTERNATIONAL CONFERENCE ON CACHEXIA, SARCOPENIA & MUSCLE WASTING

ROME
8-10 DECEMBER 2017

Follow us on www.cachexia.org

> Cachexia in Cancer, Heart Failure, COPD, CKD and Stroke
> Sarcopenia, Frailty and the Dysmobility Syndrome
> Pathophysiology and Epidemiology of Muscle Wasting
> Body Composition Assessments
> Screening, Diagnostic and Management
> Special Populations
> Clinical Trial Data

Rapid fire abstracts sessions
Young investigator awards
Plenty of time for discussion
Dear Colleague,

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is pleased to invite you to attend its 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting that will be held on December 8-10, 2017, in Rome, Italy.

As an international and multidisciplinary organization, the SCWD seeks to further research on cachexia, sarcopenia and muscle wasting in order to bring practical solutions to healthcare teams worldwide.

Since the first cachexia conference that took place in Berlin in 2000, over 2000 physicians from over 25 countries have attended our educational sessions.

We expect this SCWD conference in 2017 to be a unique forum for all medical professionals dealing with muscle wasting in their disciplines and we look forward to meeting you in Rome.

We have already more than 180 abstracts and that is very encouraging.

Looking forward to meeting you in Rome.

Yours sincerely,

John E. Morley
Stefan D. Anker

CHAIRMEN:
John E. Morley, St. Louis, MO, USA
Stefan D. Anker, Berlin, Germany

INTERNATIONAL SCIENTIFIC COMMITTEE:
Stefan D. Anker (President) – Berlin, Germany
John E. Morley – St. Louis, USA
William J. Evans – Durham, USA
Akio Inui – Kobe, Japan
Josep M. Argiles – Barcelona, Spain
Filippo Rossi-Fanelli – Rome, Italy
Vickie E. Baracos – Edmonton, Canada
Andrew Coats, Melbourne, Australia and Warwick, UK
Wolfram Doehner – Berlin, Germany
Luigi Ferrucci – Baltimore, USA
David J. Glass – Boston, USA
Aminah Jatoi – Rochester, USA
Kamyar Kalantar-Zadeh – Torrance, USA
Maurizio Muscaritoli – Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany
FRIDAY, 8 DECEMBER 2017

MORNING

8:00-8:45  Special sessions: pre-registrations only

Statistical Seminar
CHAIRS: Jennifer Le-Rademacher, USA
        Jeffrey Crawford, USA

Ken Fearon Career Café – Meet the Mentor
Coordinated by Mitja Lainscak, Slovenia

9:00-10:50  Opening SESSION 1

CHAIRS:
Stefan Anker, Germany
Maurizio Muscaritoli, Italy
Filippo Rossi-Fanelli, Italy

Welcome by the Chairs

"Hippocrates" clinical science key note lecture:
Role of mitochondria in age-related muscle impairment
Luigi Ferrucci, USA

Frailty in 2017
Bruno Vellas, France

Sex differences in cachexia, sarcopenia and wasting disorders
James Carson, USA

Research gaps from the NCI consensus
Joanne Elena, USA

Sarcopenia and cachexia: managing patients in an integrated
health care system care: a payer perspective
Bette Caan, USA

10:50-11:20  Coffee break

11:20-13:00  Opening SESSION 2

CHAIRS:
Josep Argiles, Spain
Andrea Bonetto, USA

"Prometheus" basic science key note lecture – Sarcopenia revisited:
etiology and consequences
William Evans, USA

News from proteomic and gene expression data related to aging
and cachexia
H. Alexander Ebhardt, Ireland

Cause of death in sarcopenia & cachexia
Stefan Anker, Germany

Metabolic modulation by nutrients
Maurizio Muscaritoli, Italy

Precision medicine for cachexia
John Morley, USA

13:15-14:15  Lunch symposium sponsored by Helsinn

14:30-16:00  Translating sarcopenia research across diseases

CHAIR: Zudin Puthucheary, UK
Linda Denehy, Australia

Skeletal muscle ammonia metabolism in non-hepatological
disease
Srinivasan Dasarathy, USA

Kidney dysfunction as a contribution to muscle wasting in
chronic illness
Giacomo Garibotto, Italy

Separating inflammation and deconditioning as contributors
to muscle wasting in COPD
Paul Greenhaff, UK

Molecular signaling homology across muscle wasting
conditions
Dario Coletti, Italy

Sarcopenia in 2017 – what is new?
Francesco Landi, Italy

16:00-17:00  Coffee break & science

16:05-16:55  Rapid Fire Abstract Session 1

CHAIRS:
Andrea Bonetto, Italy
David Waning, USA

16:10-16:50  Rapid Fire Abstract Session 1

17:00-18:30  Welcome reception & poster viewing

AFTERNOON

14:30-16:00  Mechanisms of muscle wasting

CHAIRS: Denis Guttridge, USA
Paola Costelli, Italy

Autophagy dysregulation in muscle stem cells during aging
Marco Sandri, Italy

Mechanisms of pathological replacement of skeletal muscle
tissue with adipose tissue
Renata Dmitrieva, Russia

Alterations in beta adrenoreceptor activity and muscle vs.
tissue wasting
Jochen Springer, Germany

ER stress and UPR in skeletal muscle health and disease
Ashok Kumar, USA

Role of JAK/STAT signalling in muscle wasting
Teresa Zimmers, USA

Mitochondrial impairment in skeletal muscle wasting
Antonio Zorzano, Spain

16:00-16:45  Poster Viewing Session 1

16:10-16:50  Rapid Fire Abstract Session 1

17:00-18:00  Biological versus numerical aging

CHAIRS: Jann Arends, Germany
          Roger Fielding, USA

DNA methylation and the biological clock
Simone Ecker, UK

Frailty scoring: biological aging phenotypes in the critically
ill survivors
Zudin Puthucheary, UK

Relationship between aging and physiological function
Stephen Harridge, UK

Nutritional status and satiety and the interaction with
biological ageing
Alessandro Laviano, Italy

Panel discussion
MORNING

7:45-8:45 Joint session of SCWD & ESPEN
CHAIRS: Stefan Anker, Germany
Maurizio Muscaritoli, Italy

The GLIM and nutrition concept
Tommy Cederholm, Sweden

Is cachexia truly malnutrition?
John Morley, USA

Panel discussion
Stefan Anker, Josep Argilés, Vickie Baracos, Tommy Cederholm, Andrew Coats, Bill Evans, John Morley, Maurizio Muscaritoli

8:00-8:45 Special sessions: pre-registrations only

Statistical Seminar
CHAIRS: Jennifer Le-Rademacher, USA
Jeffrey Crawford, USA

Ken Fearon Career Café – Meet the Mentor
Coordinated by Mitja Lainscak, Slovenia

9:00-10:30

Recent developments and updates on CT imaging for body composition analysis
CHAIRS: Andrew Coats, UK
Joanne Elena, USA

Methodological standards of CT imaging and its use as endpoint in clinical trials
Vickie Baracos, Canada

Clinical practice of anti-cancer treatment dose adaption by muscle mass data
Florian Strasser, Switzerland

CT based muscle radiodensity as prognostic marker
Sami Antoun, France

CT based assessment of muscle mass in clinical trials: the reality check and industry view
Jeffrey Crawford, USA

Advances in automatic CT image segmentation - application for body composition analysis?
Kartek Popuri, Canada

CT imaging in phase 2/3 trials - what the regulators expect to see?

9:30-10:10 Coffee break & science

10:00-10:45 Poster Viewing Session 2

10:40-11:20 Rapid Fire Abstract Session 2

CHAIRS: Egidio Del Fabbro, USA and Paul Gregorevic, Australia

11:30-13:00

Muscle loss in liver diseases
CHAIRS: Srinivasan Dasarathy, USA
Pankaj Singh, USA

Epidemiology and clinical significance of sarcopenia in liver cirrhosis
Mathias Plauth, Germany

Significance of sarcopenia and sarcopenic obesity in fatty liver
Manuela Merli, Italy

Molecular mechanisms of sarcopenia in liver cirrhosis
Michela Giusto, Italy

Role of HIF in muscle wasting
Steven Olde Damink, The Netherlands

Treatment approaches for muscle wasting in liver cirrhosis
Srinivasan Dasarathy, USA

13:15-14:15 Lunch symposium sponsored by Stealth Biotheapeutics

11:30-13:00

H Muscle mass regulation and muscle mass assessment
CHAIRS: Stephan von Haehling, Germany
William Evans, USA

Ubiquitination and Deubiquitination – update 2017
Didier Attaix, France

MrOs: Longitudinal observational trial in older men – body composition and outcomes
Peggy Cawthon, USA

The D3-creatine dilution method: methodology & new data
Eric Orwoll, USA

The need for accurate assessment of body composition in infants and children
Daniel Marks, USA

SPRINT-T – update 2017
Roberto Bernabei, Italy

11:30-13:00

I Young investigators awards session

Nutritional approaches to combat sarcopenia & cachexia
CHAIR: Nicolaas Deutz, USA
Alessandro Laviano, Italy

Judges: Samuel Breit, Australia
Wolfram Doehner, Germany
David Glass, USA
Robert Mak, USA
Giovanni Mantovani, Italy
Teresa Zimmers, USA

11:30-13:00

J Muscle loss in liver diseases
CHAIRS: Srinivasan Dasarathy, USA
Pankaj Singh, USA

Epidemiology and clinical significance of sarcopenia in liver cirrhosis
Mathias Plauth, Germany

Significance of sarcopenia and sarcopenic obesity in fatty liver
Manuela Merli, Italy

Molecular mechanisms of sarcopenia in liver cirrhosis
Michela Giusto, Italy

Role of HIF in muscle wasting
Steven Olde Damink, The Netherlands

Treatment approaches for muscle wasting in liver cirrhosis
Srinivasan Dasarathy, USA

13:15-14:15 Lunch symposium sponsored by Stealth Biotheapeutics

11:30-13:00

K Cachexia: not just muscle
CHAIRS: James Carson, USA
Jochen Springer, Germany

The bone-muscle cross-talk
David Waring, USA

Adipogenic drive in cancer-induced muscle wasting
Paola Costelli, Italy

Energy metabolism, mitochondria and cachexia in COPD
Anneemie Schols, The Netherlands

Metabolic regulation of fat in cancer cachexia
Stefan Herzog, Germany

Protecting fat to gain muscle – a possible new therapeutic concept?
Jeffrey Crawford, USA

11:30-13:00

L Nutritional approaches to combat sarcopenia & cachexia
CHAIR: Nicolaas Deutz, USA
Alessandro Laviano, Italy

Malnutrition and cachexia in cancer patients at first medical oncology visit
Maurizio Muscaritoli, Italy

Micronutrients in sarcopenia and age-related physical decline
Jerome Feige, Switzerland

Interaction exercise and nutrition in sarcopenia
Roger Fielding, USA

The efficacy of a novel oral nutrition supplement in tackling sarcopenia in the elderly
Pol Grootswagers, The Netherlands

Proteins to treat sarcopenia
Jürgen Bauer, Germany

Trial experience in wasting disorders using nutritional approaches
Jann Arends, Germany
### Models of cachexia

**CHAIRS:** Stefan Herzig, Germany  
Jochen Springer, Germany

- Human xenografts as a suitable model for studying cancer cachexia  
  Andrew Judge, USA
- Modeling cachexia: the impact of anti-neoplastic therapy  
  Andrea Bonetto, USA
- Experimental models for aging and sarcopenia  
  Sue-Joan Chang, Taiwan
- New experimental model of cancer cachexia & kidney disease  
  Daniel Marks, USA
- Large animal models of human cachexia: update 2017  
  Lisa Freeman, USA

### Cachexia at its worst

**CHAIRS:** Vickie Baracos, Canada  
Stephan von Haehling, Germany

- Diagnostic criteria for the classification of cancer-associated weight loss  
  Egidio Del Fabbro, USA
- Wasting of muscle involved in swallowing and mastication  
  Florian Strasser, Switzerland
- Diagnosis and management of oropharyngeal dysphagia  
  Anne Letsch, Germany
- Treating shortness of breath in advanced cancer cachexia – the muscle hypothesis  
  Andrew Coats, UK
- Palliative care and anabolic therapies  
  Aminah Jatoi, USA

### Targeting skeletal muscle – from research to clinical development

**CHAIRS:** Ashok Kumar, USA  
Antonio Zorzano, Spain

- Biopsies of skeletal muscle – a source of new understanding  
  Volker Adams, Germany
- Muscle satellite cells  
  Camila Almeida, Brazil
- Diabetes and muscle  
  Leocadio Rodríguez Mañas, Spain
- Gene therapy approaches to treat cancer cachexia  
  Paul Gregorevic, Australia
- Cachexia & sarcopenia – how to develop and get approved drugs there  
  Giuseppe Rosano, UK

### Coffee break & science

**CHAIRS:** Josep Argiles, Spain and Aminah Jatoi, USA

### Rehabilitation in advanced elderly cancer patients with cachexia

**CHAIRS:** Paolo Bossi, Italy  
Florian Strasser, Switzerland

- Muscle of the elderly and physical activity: balancing over- and undertreatment  
  Francesco Landi, Italy
- Exercise training as an effective tool to improve cancer-induced muscle wasting  
  Fabio Penna, Italy
- What can cancer cachexia rehabilitation trials learn from critical care rehabilitation?  
  Linda Denehy, Australia
- Rehabilitative-geriatric interventions in elderly advanced cancer patients: who will respond?  
  Pierre Soubeyran, France
- Perspectives of health care professionals on cancer cachexia: results from three global surveys  
  Alessio Moffino, Italy

### Potential treatments for muscle wasting and cachexia

**CHAIR:** Volker Adams, Germany  
Marco Sandri, Italy

- MEK inhibitors as potential tools to improve cancer-induced muscle wasting  
  Erin Talbert, USA
- MAGIC-F1 modulations to improve myogenesis  
  Maurilio Sampaolesi, Italy
- New drug targets from a neglected hormone? Unacylated Ghrelin and the regulation of muscle mass and muscle repair  
  Andrea Graziani, Italy
- Drugs modifying catabolic/anabolic balance: ACE inhibitors + beta-blockers  
  Mitja Lainscak, Slovenia
- What else is new?  
  William Evans, USA

### Muscle wasting and cachexia in chronic illnesses – update 2017

**CHAIRS:** Annemie Schols, The Netherlands  
Giacomo Garibotto, Italy

- COPD  
  Stefan Andreas, Germany
- Chronic heart failure  
  Stephan von Haehling, Germany
- Chronic kidney disease failure  
  Robert Mak, USA
- Stroke  
  Wolfram Doehner, Germany
- Cancer  
  Jeffrey Crawford, USA
SUNDAY, 10 DECEMBER 2017

**Imaging methods for assessing muscle mass**

**CHAIRS:** Vickie Baracos, Canada  
Steven Heymsfield, USA

- **Body impedance**  
  M. Christina Gonzalez, Brazil

- **Cross-sectional: CT or MRI**  
  Vickie Baracos, Canada

- **Quadriceps contractile volume by MRI**  
  Thomas Maden-Wilkinson, UK

**Ultra-sound methods**

- Thiago Gonzalez Barbosa-Silva, Brazil

**Panel discussion**

---

**Clinical trials in progress**

**CHAIRS:** Aminah Jatoi, USA  
Andrew Coats, UK

- **Re-testing fish oil for cachexia**  
  Maria Öhlander, Norway

- **Pluripotent cells to treat muscle wasting after orthopedic surgery**  
  Tobias Winkler, Germany

- **Peptamen for weight loss**  
  Andrew Hendifar, USA

- **Cannabis for cancer-associated weight loss**  
  Moran Grinberg, Israel

- **Rare disease drug development considerations**  
  Anthony Audi, USA

---

**Intensive care unit myopathy and beyond: Molecular signals and clinical observations**

**CHAIRS:** William Evans, USA  
Samuel Breit, Australia

- **Introduction and historical data: nutritional intervention strategies**  
  Nicolaas Deutz, USA

- **Inflammation as a trigger for rapid loss of muscle: pre-clinical and clinical data**  
  Paul Greenhaff, UK

- **Molecular signals in skeletal muscle from ICU patients: the role of GDF-15**  
  Mark Griffiths, UK

- **GFRα1, the receptor for GDF15**  
  Shamina Rangwala (USA)

- **Clinical experience: treating muscle wasting in the ICU**  
  Tobias Wollersheim, Germany

---

**Awards Ceremony**

- **Best Poster Award**  
- **Young Investigators Award**  
- **Trainee Poster Award**
EDUCATIONAL OBJECTIVES:
Following this activity, the audience will be able to:
1. Review the latest information about the pathophysiology of muscle wasting and its epidemiology.
2. Screen for and diagnose cachexia, sarcopenia, frailty and dysmobility resulting from the following diseases or chronic conditions: cancer, cardiovascular disease, COPD, CKD, dementia/Alzheimer’s disease, diabetes, infectious diseases, stroke and aging.
3. Develop appropriate management programs for patients across the continuum of care.

TARGET AUDIENCE:
Internists, oncologists, cardiologists, gerontologists, palliative care specialists, primary care physicians and nurses.

Online registration: www.cachexia.org

Organization
MEDED GLOBAL SOLUTIONS
27, rue Raffet, 75016 Paris, France
Tel: +33 (0)1 44 01 51 81
Fax: +33 (0)1 44 01 51 80
E-mail: scwd@mededgs.com

www.cachexia.org

DATES
Friday, December 8, 2017 to Sunday, December 10, 2017

ABSTRACTS
All abstracts will be published in the Journal of Cachexia, Sarcopenia and Muscle (JCSM).

VENUE
Sheraton Roma Hotel & Conference Center
Viale Del Pattinaggio, 100
Rome, 00144, Italy

> Official language: English